Quick Reference Guide
Click on the link below for our quick reference guide on managing Osteosarcoma.
Managing Osteosarcoma
Click on the link below for our quick reference guide on managing Osteosarcoma.
Managing Osteosarcoma
Pain is the unpleasant sensation that develops with the stimulation of specialized sensory nerve endings, called pain receptors. Pain most often develops from damage, irritation or inflammation of tissues or structures of the body. Pain is a protective mechanism. It causes the animal to react and to move away from the source of the stimulus.
Manifestations of pain are highly variable in animals. Some signs are obviously related to pain, while others are more subtle. The individual personality of the animal and its tolerance for pain also affect the clinical manifestations of pain. Animals in pain often present with a wide variety of signs. Some signs that are associated with pain include the following:
Palliative therapy is "comfort care"-it is intended to maintain a good quality of life for patients in whom long-term cancer control is not possible. Palliative radiation therapy (PRT) can be used to control symptoms that cannot be relieved surgically or by other means...in the case of osteosarcoma, it may be indicated for patients who are not candidates for amputation. It might also be indicated for treatment of painful bone metastases (spread to other bones) even after amputation, under specific circumstances. The goal of PRT is to provide relief of symptoms, not to cure the cancer.
Ask your radiation oncologist if a bone scan is necessary before starting the PRT, to look for other bone areas that might be involved, even without symptoms. You should also ask about the possibility of combining the PRT with chemotherapy if your dog is not a candidate for amputation.
PRT is particularly useful to alleviate pain from osteosarcoma (bone cancer). It is usually combined with pain medications. Approximately 65% of patients will show a moderate to significant improvement in symptoms, and the effects can last for several weeks to several months. It may begin to have effect several days after the first treatment, or it may take a few weeks before improvement is noted.
PRT delivers radiation over a period of time. The treatment plan should be discussed with the radiation oncologist, regarding frequency and interval between treatments. The procedure requires anesthesia because the dog must remain perfectly still, and the dog should not eat on the day of the procedure.
Aside from the potential side effects of anesthesia, side effects from PRT are usually limited to the area involved by radiation. The side effects usually begin several weeks after PRT has started, and can last several weeks. The skin area that receives PRT will be pink or even red, with loss of hair and possibly some flaking or dryness of the skin. This is known as "radiation dermatitis". In some cases it will look like a severe sunburn or even a blistering rash. Topical medications prescribed by the veterinarian may help, and preventing the dog from licking, rubbing or scratching the treated area will also be of benefit. Eventually the skin will become very dark, even black and there may be some hair re-growth. Long term side effects such as risk of non-healing wounds usually occur after a year, but are much less common due to the life expectancy of most dogs with osteosarcoma treated with PRT.
It is unusual for dogs to develop nausea or vomiting from PRT, unless part of the abdomen is involved in the radiation field. If PRT is being recommended for bones involving the head/skull, there can be side effects involving the eyes or mucous membranes and salivary glands of the mouth. These side effects should be discussed in detail with your radiation oncologist.
Please note: PRT cannot be used in conjunction with artemisinin, an herb that is frequently used in the management of osteosarcoma. If your dog is currently taking artemisinin and you are considering PRT, the artemisinin must be stopped for at least several weeks.
Back to the top.
The aim of the limb sparing procedure is to save the leg instead of performing an amputation. The goal is to provide a functional, pain-free leg while not jeopardizing the chances of survival. Medical indications for limb sparing include previous amputation of another limb, severe concurrent osteoarthritis, or neurologic disease. For example, in over 300 limb sparing surgeries performed at Colorado State University, 85% of the patients have experienced good to excellent function. The average survival after limb sparing and chemotherapy is 50% or better at 1 year, which is equal to the survival of dogs receiving amputation and chemotherapy.
It is extremely important to determine if the dog is a candidate for limb sparing procedure. The pretreatment evaluation should include a CBC, urinalysis, biochemical profile (paying particular emphasis to the serum alkaline phosphatase, which can have negative prognostic implications), chest x-ray, and a bone survey or nuclear bone scan. 10-15% of patients will have multiple lesions at the time of diagnosis which carries a worse prognosis. Pathologic fractures are a relative contraindication due to soft tissue contamination via hemorrhage and hematoma. If there is evidence of spread of the cancer, limb sparing surgery is not an option.
Limb sparing surgery is most successful for dogs with primary bone tumors in the distal radius and ulna. Dogs with osteosarcoma of the front leg at the "wrist" (distal radius or ulna) with no evidence of cancer spread to other sites in the body may be candidates for limb sparing. Candidates for limb sparing surgery include dogs with tumors confined to the bone, minimal extension into adjacent soft tissue, and involvement of less than 50% of the bone length. The extent of bone involvement is most accurately determined using CT scans. Other locations are often associated with higher rate of complications and poor postoperative limb function.
To see if your dog is eligible for a limb sparing, several tests will be done, such as blood tests, x-rays, bone scan, ultrasound or computed tomography scans to look for evidence of cancer in other parts of the body. If the tumor is found only in the leg, then limb sparing may be an option. If limb sparing is contemplated, the biopsy technique and position should be carefully planned. Preoperative treatment with cisplatin (chemotherapy) and radiation makes the surgery easier and decreases the chance of recurrence. The optimal dose, route of delivery, and timing of cisplatin relative to the radiation is still unclear. However, this adds significantly to the cost of treatment and is not commonly used.
In limb sparing surgery, the tumor and the affected piece of bone are removed. The space created after the tumor removal is usually filled with an allograft, autograft, or metal implant. An allograft is sterile, frozen bone that has been stored in a bone bank and harvested from dogs that died of other causes. An autograft involves surgically separating the tumor site from the leg and then treating it with a high dose of radiation to "kill" the tumor. Once the allograft, autograft or metal implant is inserted into the defect, a stainless steel plate is applied, and the wrist is fused. The plate is not removed unless it causes problems. Although the wrist can no longer bend, this is not painful and dogs can use the leg almost normally as they compensate by increasing elbow and shoulder motion. In some cases, dogs with tumors of the ulna may not require an allograft or fusion of the wrist.
The surgery itself takes about 2 to 3 hours, but generally anesthesia may last 4 to 5 hours. Dogs stay in the hospital for 2-4 days after surgery. After surgery, a soft padded bandage (usually not a cast or splint) will be applied to the leg, to prevent licking of the wound. The bandages may be changed every few days. Elizabethan collars should be used for dogs who are adamant about licking the bandages. Weight-bearing and range-of-motion exercises can be started immediately after surgery but should be restricted to leashed walks for the first 4 weeks. Exercise is important to prevent contractures of the toes and to decrease swelling in the limb. Most dogs resume normal activities within one to two months after surgery. Medications that are routinely used after surgery include antibiotics and pain medications.
Chemotherapy is usually be started 2 weeks after surgery, with drugs such as cisplatin, carboplatin, or doxorubicin. Four to six treatments, 3 weeks apart, may be recommended depending on the drugs used. This is necessary to try and prevent metastatic cancer. If no chemotherapy is given, there is only a 10% chance that your dog will be alive one year after surgery. However, if chemotherapy is given, the one-year survival probability is 50% and the 2-year survival is 30%.
The most commonly reported complications with limb-sparing surgery are implant failure, local tumor recurrence, and infection. Implant failure occurs in approximately 10% of cases. The use of an orthopedic cement known as methylmethacrylate reduces the incidence of screw loosening, implant failure, and fracture. Local tumor recurrence is caused by incomplete resection or, more commonly, residual neoplastic cells in the soft tissue adjacent to the tumor capsule after marginal resection of the primary bone tumor.
Infection is the most significant postoperative complication encountered with limb-sparing surgery. The cause of infection is unknown, although the extensive resection of soft tissues, poor soft tissue coverage, use of orthopedic implants, and administration of local and systemic chemotherapy are thought to contribute. The use of antibiotic impregnated cement has decreased the risk of infection, which was about 40%. Initially, infections are treated with antibiotics, saline lavages, and wet-to-dry bandages. If the infection is unresponsive or recurs despite treatment, antibiotic-impregnated methylmethacrylate beads can be surgically implanted adjacent to the infected bone. Amputation of the limb may be necessary as a salvage procedure in dogs with uncontrollable infection.
There is generally less than a 20% chance that the tumor will regrow in the leg (local recurrence). Insertion of an absorbable chemotherapy (cisplatin) sponge into the wound at the time of surgery decreases the chances of local recurrence. The chemotherapy sponge is a biodegradable polymer, which slowly breaks down in the body, releasing cisplatin in very high concentrations to the tissues in the surgery site. Only a low dose of cisplatin gets into the blood stream. This high local dose of cisplatin will kill cancer cells remaining in the leg after limb sparing surgery. This material does not usually affect healing, is well tolerated and does not cause noticeable side effects.
Periodic physical examinations as well as chest and leg x-rays will be necessary to follow the dog's progress. Unless covered by a funded study, the cost of a limb spare surgery ranges from $3,500-$5,000, depending on the amount of the work-up already done by your veterinarian. Follow-up chemotherapy can range from $1,000-$4,000, depending on the drugs chosen. The total cost for one year of treatment and follow-up can be as high as $10,000. It is possible that your dog may be eligible for certain trials investigating various aspects of limb sparing and the treatment of OSA.
Back to the top.
BISPHOSPHONATES-Please discuss all information with your vet
In humans, bisphosphonates are used to treat osteoporosis and to help lower high calcium levels due to certain types of cancer. They are also used to stabilize bones that are at risk for fracture from metastatic cancer or from multiple myeloma. The most common bisphosphonates are oral alendronate (Fosamax), oral risedronate (Actonel) and intravenous pamidronate (Aredia).
In dogs, bisphosphonates are used as adjuvant therapy for the management of osteosarcoma. They inhibit osteoclast cells which are responsible for bone breakdown. This inhibition gives the osteoblast cells (bone builders) a chance to work without interference, strengthening the existing bone and creating new bone. Increasing the strength of the existing bone helps to decrease the risk of fractures, and stronger bone is less painful.
When studied in the laboratory, bisphosphonates also have a direct toxic effect on bone cancer cells, contributing to their death. There is also evidence that by inhibiting the growth of new blood vessels within the cancer, they also inhibit cancer growth.
The most commonly used bisphosphonate in the treatment of bone cancer in dogs is the intravenous pamidronate. It is used often in conjunction with radiation therapy, given in several cycles every few weeks. Recent studies have also shown that the oral alendronate may have a similar role in the stabilization of cancerous bone, by increasing the formation of healthy bone and decreasing the risk of fracture. There can be significant improvement in pain when bisphosphonates are used. Ongoing research suggests that bisphosphonates may also have a role in the inhibition of metastatic bone cancer cells, by their direct toxic effect. The indication for their use after amputation and chemotherapy remains to be defined, but there is promising laboratory evidence to support this theory.
The major side effects of bisphosphonates include gastrointestinal toxicity (nausea, vomiting, diarrhea or change in appetite) and kidney toxicity. Urine tests and electrolyte and kidney blood tests should be checked prior to institution of therapy and periodically during treatment, particularly if other medications such as anti-inflammatories are being prescribed. Intravenous pamidronate is usually administered over several hours. When the oral alendronate is prescribed, it is usually administered in the morning as a single dose, followed by a small meal 30 minutes later.
Back to the top.
Metronomic:low dose, continuous timed intervals
The metronomic protocol can be used at all stages. No amputation, maintenance protocol (with or without chemo), and the onset of lung mets. Individual components can be given as stand-alone.
Major components:
DOXYCYCLINE-Please discuss all information with your vet
Doxycycline is used as part of the metronomic protocol in conjunction with cyclophosphamide and anti-inflammatory medicines such as piroxicam or carprofen (Rimadyl)for the management of canine osteosarcoma.
The principles behind its use include: